Chemistry:BMY-14802

From HandWiki
Short description: Chemical compound
BMY-14802
BMY-14802 Structure.svg
Clinical data
Other namesBMS-181100; MJ-14802
ATC code
  • None
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC18H22F2N4O
Molar mass348.398 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

BMY-14802, also known as BMS-181100, is a drug with antipsychotic effects which acts as both a sigma receptor antagonist and a 5-HT1A receptor agonist.[1][2][3][4] It also has affinity for the 5-HT2 and D4 receptors.[5] The drug reached phase III clinical trials for the treatment of psychosis but was never marketed.[6]

See also

References

  1. "A role for sigma binding in the antipsychotic profile of BMY 14802?". NIDA Research Monograph 133: 125–157. 1993. PMID 8232511. 
  2. "Discriminative stimulus characteristics of BMY 14802 in the pigeon". The Journal of Pharmacology and Experimental Therapeutics 284 (1): 1–9. January 1998. PMID 9435153. 
  3. "Sigma1 receptor antagonists determine the behavioral pattern of the methamphetamine-induced stereotypy in mice". Psychopharmacology 203 (4): 781–792. May 2009. doi:10.1007/s00213-008-1425-z. PMID 19052726. 
  4. "The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism". Psychopharmacology 204 (4): 743–754. July 2009. doi:10.1007/s00213-009-1505-8. PMID 19283364. 
  5. "Sigma 1 Receptor Chaperone: Pharmacology and Therapeutic Perspectives". Therapeutic Targets: Modulation, Inhibition, and Activation. John Wiley & Sons. 20 April 2012. pp. 248–. ISBN 978-1-118-18552-0. https://books.google.com/books?id=3XJ8PXFCXq4C&pg=PA248. 
  6. "BMS 181100". AdisInsight. Springer Nature Switzerland AG. http://adisinsight.springer.com/drugs/800000679.